Tango Therapeutics, Inc. (NASDAQ:TNGX - Get Free Report) insider Mva Investors, Llc sold 60,000 shares of Tango Therapeutics stock in a transaction dated Friday, May 3rd. The shares were sold at an average price of $7.61, for a total value of $456,600.00. Following the sale, the insider now owns 483,524 shares of the company's stock, valued at $3,679,617.64. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink.
Mva Investors, Llc also recently made the following trade(s):
- On Wednesday, May 1st, Mva Investors, Llc sold 75,000 shares of Tango Therapeutics stock. The shares were sold at an average price of $7.43, for a total transaction of $557,250.00.
Tango Therapeutics Trading Up 0.3 %
NASDAQ TNGX opened at $7.61 on Friday. The company has a market cap of $812.29 million, a P/E ratio of -6.92 and a beta of 0.84. Tango Therapeutics, Inc. has a 1 year low of $2.47 and a 1 year high of $13.03. The company has a fifty day simple moving average of $8.58 and a 200 day simple moving average of $9.31.
Tango Therapeutics (NASDAQ:TNGX - Get Free Report) last released its quarterly earnings results on Monday, March 18th. The company reported ($0.32) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.28) by ($0.04). The firm had revenue of $5.43 million for the quarter, compared to the consensus estimate of $7.86 million. Tango Therapeutics had a negative net margin of 278.55% and a negative return on equity of 41.96%. Equities research analysts forecast that Tango Therapeutics, Inc. will post -1.28 EPS for the current fiscal year.
Wall Street Analysts Forecast Growth
Claim Your Complimentary Bitcoin Reward
From Crypto Swap Profits | Ad
Many have already secured their free Bitcoin reward offered by our esteemed guest. How about you?
In an effort to spread the word about our upcoming workshop, he's generously offering $10 in Bitcoin (BTC) to participants.
Absolutely no strings attached.
Secure Your Spot Now
Several research analysts have recently commented on TNGX shares. Piper Sandler started coverage on shares of Tango Therapeutics in a research note on Monday, February 12th. They set an "overweight" rating and a $18.00 price target on the stock. Cantor Fitzgerald began coverage on shares of Tango Therapeutics in a research report on Thursday, April 4th. They set an "overweight" rating on the stock. Wedbush restated an "outperform" rating and set a $18.00 target price on shares of Tango Therapeutics in a report on Monday, March 18th. Finally, HC Wainwright upped their price target on Tango Therapeutics from $16.00 to $17.00 and gave the stock a "buy" rating in a research note on Wednesday, March 20th. Five equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company currently has a consensus rating of "Buy" and an average price target of $17.25.
Read Our Latest Analysis on TNGX
Institutional Inflows and Outflows
Several institutional investors have recently added to or reduced their stakes in the business. SG Americas Securities LLC bought a new stake in shares of Tango Therapeutics in the third quarter valued at approximately $233,000. Bank of New York Mellon Corp increased its holdings in shares of Tango Therapeutics by 9.5% during the 3rd quarter. Bank of New York Mellon Corp now owns 154,673 shares of the company's stock worth $1,742,000 after purchasing an additional 13,418 shares during the period. Strs Ohio lifted its stake in shares of Tango Therapeutics by 71.9% in the third quarter. Strs Ohio now owns 23,900 shares of the company's stock valued at $269,000 after buying an additional 10,000 shares during the period. Clear Harbor Asset Management LLC increased its stake in Tango Therapeutics by 22.2% during the third quarter. Clear Harbor Asset Management LLC now owns 20,131 shares of the company's stock valued at $227,000 after acquiring an additional 3,657 shares during the period. Finally, Barclays PLC lifted its position in shares of Tango Therapeutics by 56.2% in the 3rd quarter. Barclays PLC now owns 87,882 shares of the company's stock worth $990,000 after acquiring an additional 31,618 shares during the period. 78.99% of the stock is owned by institutional investors.
Tango Therapeutics Company Profile
(
Get Free Report)
Tango Therapeutics, Inc, a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
